Literature DB >> 35861632

Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls.

Hua-Jay J Cherng1, Jason R Westin2.   

Abstract

Tafasitamab and lenalidomide were approved for second-line treatment of diffuse large B-cell lymphoma (DLBCL) based on a single-arm phase II study. This combination was superior to routine immunochemotherapy regimens when comparing matched observational cohorts. "Synthetic" control groups may support use of novel DLBCL therapies in the absence of randomized studies. See related article by Nowakowski et al., p. 4003. ©2022 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35861632      PMCID： PMC9481674          DOI： 10.1158/1078-0432.CCR-22-1626

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   13.801


  15 in total

1.  Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

Authors:  Michael Crump; Sattva S Neelapu; Umar Farooq; Eric Van Den Neste; John Kuruvilla; Jason Westin; Brian K Link; Annette Hay; James R Cerhan; Liting Zhu; Sami Boussetta; Lei Feng; Matthew J Maurer; Lynn Navale; Jeff Wiezorek; William Y Go; Christian Gisselbrecht
Journal:  Blood       Date:  2017-08-03       Impact factor: 22.113

2.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Authors:  Jeremy S Abramson; M Lia Palomba; Leo I Gordon; Matthew A Lunning; Michael Wang; Jon Arnason; Amitkumar Mehta; Enkhtsetseg Purev; David G Maloney; Charalambos Andreadis; Alison Sehgal; Scott R Solomon; Nilanjan Ghosh; Tina M Albertson; Jacob Garcia; Ana Kostic; Mary Mallaney; Ken Ogasawara; Kathryn Newhall; Yeonhee Kim; Daniel Li; Tanya Siddiqi
Journal:  Lancet       Date:  2020-09-01       Impact factor: 79.321

3.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

4.  Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.

Authors:  Nagesh Kalakonda; Marie Maerevoet; Federica Cavallo; George Follows; Andre Goy; Joost S P Vermaat; Olivier Casasnovas; Nada Hamad; Josée M Zijlstra; Sameer Bakhshi; Reda Bouabdallah; Sylvain Choquet; Ronit Gurion; Brian Hill; Ulrich Jaeger; Juan Manuel Sancho; Michael Schuster; Catherine Thieblemont; Fátima De la Cruz; Miklos Egyed; Sourav Mishra; Fritz Offner; Theodoros P Vassilakopoulos; Krzysztof Warzocha; Daniel McCarthy; Xiwen Ma; Kelly Corona; Jean-Richard Saint-Martin; Hua Chang; Yosef Landesman; Anita Joshi; Hongwei Wang; Jatin Shah; Sharon Shacham; Michael Kauffman; Eric Van Den Neste; Miguel A Canales
Journal:  Lancet Haematol       Date:  2020-07       Impact factor: 18.959

5.  RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma.

Authors:  Pier Luigi Zinzani; Thomas Rodgers; Dario Marino; Maurizio Frezzato; Anna Maria Barbui; Claudia Castellino; Erika Meli; Nathan H Fowler; Gilles Salles; Bruce Feinberg; Nuwan C Kurukulasuriya; Sascha Tillmanns; Stephan Parche; Debarshi Dey; Günter Fingerle-Rowson; Sumeet Ambarkhane; Mark Winderlich; Grzegorz S Nowakowski
Journal:  Clin Cancer Res       Date:  2021-08-25       Impact factor: 12.531

Review 6.  CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?

Authors:  Jason Westin; Laurie H Sehn
Journal:  Blood       Date:  2022-05-05       Impact factor: 22.113

7.  Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.

Authors:  Grzegorz S Nowakowski; Dok Hyun Yoon; Anthea Peters; Patrizia Mondello; Erel Joffe; Isabelle Fleury; Richard Greil; Matthew Ku; Reinhard Marks; Kibum Kim; Pier Luigi Zinzani; Judith Trotman; Dan Huang; Eva E Waltl; Mark Winderlich; Nuwan C Kurukulasuriya; Sumeet Ambarkhane; Georg Hess; Gilles Salles
Journal:  Clin Cancer Res       Date:  2022-09-15       Impact factor: 13.801

8.  Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.

Authors:  Gilles Salles; Johannes Duell; Eva González Barca; Olivier Tournilhac; Wojciech Jurczak; Anna Marina Liberati; Zsolt Nagy; Aleš Obr; Gianluca Gaidano; Marc André; Nagesh Kalakonda; Martin Dreyling; Johannes Weirather; Maren Dirnberger-Hertweck; Sumeet Ambarkhane; Günter Fingerle-Rowson; Kami Maddocks
Journal:  Lancet Oncol       Date:  2020-06-05       Impact factor: 41.316

9.  T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Steven M Horwitz; Stephen Ansell; Weiyun Z Ai; Jeffrey Barnes; Stefan K Barta; Jonathan Brammer; Mark W Clemens; Ahmet Dogan; Francine Foss; Paola Ghione; Aaron M Goodman; Joan Guitart; Ahmad Halwani; Bradley M Haverkos; Richard T Hoppe; Eric Jacobsen; Deepa Jagadeesh; Allison Jones; Avyakta Kallam; Youn H Kim; Kiran Kumar; Neha Mehta-Shah; Elise A Olsen; Saurabh A Rajguru; Sima Rozati; Jonathan Said; Aaron Shaver; Lauren Shea; Michi M Shinohara; Lubomir Sokol; Carlos Torres-Cabala; Ryan Wilcox; Peggy Wu; Jasmine Zain; Mary Dwyer; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2022-03       Impact factor: 12.693

10.  Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; Patrick M Reagan; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; Michael Crump; John Kuruvilla; Eric Van Den Neste; Umar Farooq; Lynn Navale; Venita DePuy; Jenny J Kim; Christian Gisselbrecht
Journal:  Blood Adv       Date:  2021-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.